Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 518-523

  Guerra, Iván ^a   Algaba, Alicia ^a   Pérez Calle, José Lázaro ^b   Chaparro, María ^c   Marín Jiménez, Ignacio ^d   García Castellanos, Raquel ^e   González Lama, Yago ^f   López Sanromán, Antonio ^g   Manceñido, Noemí ^h   Martínez Montiel, Pilar ⁱ   Quintanilla, Elvira ^j   Taxonera, Carlos ^k   Villafruela, Mónica ^l   Romero Maté, Alberto ^a   López Serrano, Pilar ^b   Gisbert, Javier P ^c   Bermejo, Fernando ^a  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL SEVERO OCHOA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

more..

Author keywords

Adalimumab; Crohn's disease; Inflammatory bowel disease; Infliximab; Psoriasis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ARTICLE; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LIMB; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SCALP; SCALP PSORIASIS; SPAIN; TREATMENT DURATION; TRUNK; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84860835230     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.007     Document Type: Article

References (36)

1. Spoettl T., Hausmann M., Klebl F., Dirmeier A., Klump B., Hoffmann J., et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis 2007, 13(6):727-732.
2. Bradley J.R. TNF-mediated inflammatory disease. J Pathol 2008, 214(2):149-160.
3. Sandborn W.J. State-of-the-art: immunosuppression and biologic therapy. Dig Dis 2010, 28(3):536-542.
4. Feldmann M., Maini R.N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. J Immunol 2010, 185(2):791-794.
5. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20(2):100-108.
6. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. discussion 16-19.
7. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
8. de Gannes G.C., Ghoreishi M., Pope J., Russell A., Bell D., Adams S., et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007, 143(2):223-231.
9. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., Sandborn W.J. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011, 17(1):471-478.
10. Park J.J., Lee S.C. A case of tumor necrosis factor-alpha inhibitors-induced pustular psoriasis. Ann Dermatol 2010, 22(2):212-215.
11. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D.A., et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161(5):987-1019.
12. Palucka A.K., Blanck J.P., Bennett L., Pascual V., Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005, 102(9):3372-3377.
13. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202(1):135-143.
14. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005, 52(8):2513-2518.
15. Baeten D., Kruithof E., Van den Bosch F., Van den Bossche N., Herssens A., Mielants H., et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum Dis 2003, 62(9):829-834.
16. Lee H.H., Song I.H., Friedrich M., Gauliard A., Detert J., Rowert J., et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007, 156(3):486-491.
17. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clin Infect Dis 2005, 41(Suppl 3):S199-S203.
18. Rallis E., Korfitis C., Stavropoulou E., Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?. J Dermatolog Treat 2010, 21(1):3-5.
19. Harrison M.J., Dixon W.G., Watson K.D., King Y., Groves R., Hyrich K.L., et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009, 68(2):209-215.
20. Rahier J.F., Buche S., Peyrin-Biroulet L., Bouhnik Y., Duclos B., Louis E., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8(12):1048-1055.
21. Bernstein C.N., Wajda A., Blanchard J.F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129(3):827-836.
22. Zandman-Goddard G., Peeva E., Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007, 6(6):366-372.
23. Iborra M., Beltran B., Bastida G., Aguas M., Nos P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis 2011, 5(2):157-161.
24. Pourciau C., Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol 2010, 27(5):539-540.
25. Costa-Romero M., Coto-Segura P., Suarez-Saavedra S., Ramos-Polo E., Santos-Juanes J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008, 14(10):1462-1463.
26. Avila Alvarez A., Garcia-Alonso L., Solar Boga A., Garcia-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An Pediatr (Barc) 2009, 70(3):278-281.
27. Wollina U., Hansel G., Koch A., Schonlebe J., Kostler E., Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9(1):1-14.
28. Fiorino G., Allez M., Malesci A., Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29(9):921-927.
29. Cleynen I., Van Moerkercke W., Juergens M., Ballet V., Drobne D., Vandecandelaere P., et al. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut 2010, 59(Suppl III):A1.
30. Santos-Juanes J., Galache C. Psoriasiform skin reactions during treatment with etanercept. Actas Dermosifiliogr 2010, 101(Suppl 1):106-110.
31. Collamer A.N., Guerrero K.T., Henning J.S., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59(7):996-1001.
32. Eriksson M.O., Hagforsen E., Lundin I.P., Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol 1998, 138(3):390-398.
33. Michaelsson G., Kajermo U., Michaelsson A., Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?. Br J Dermatol 2005, 153(6):1243-1244.
34. Borras-Blasco J., Navarro-Ruiz A., Borras C., Castera E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 2009, 102(11):1133-1140.
35. Laga A.C., Vleugels R.A., Qureshi A.A., Velazquez E.F. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. a study of 16 biopsies. Am J Dermatopathol 2010, 32(6):568-573.
36. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40(3):233-240.